Skip to Content
Merck

Key Documents

View All Documentation

L1764

(±)-Lorazepam

Synonym(s):

7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C15H10Cl2N2O2
CAS Number:
846-49-1
Molecular Weight:
321.16
NACRES:
NA.77
PubChem Substance ID:
24896291
UNSPSC Code:
12352200
EC Number:
212-687-6
MDL number:
MFCD00063406
Quality level:
200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

200

drug control

USDEA Schedule IV; Home Office Schedule 4.1; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet, kontrollierte Droge in Deutschland

originator

Baxter

SMILES string

OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O

InChI

1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

InChI key

DIWRORZWFLOCLC-UHFFFAOYSA-N

Gene Information

human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), GABRD(2563), GABRE(2564), GABRG1(2565), GABRG2(2566), GABRG3(2567), GABRP(2568), GABRQ(55879)

Biochem/physiol Actions

Anxiolytic; ligand for the GABAA receptor benzodiazepine modulatory site.

Features and Benefits

This compound was developed by Baxter. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361d

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000271056
0000271056
127F08281
127F0828
035F0115

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S Korkmaz et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 8(3), 175-181 (1998-08-26)
Rats were treated with lorazepam for four days (six times 2 mg kg(-1)) at the ages of 71, 118, 163 and 210 days. Increased excitation (physical dependence) in the withdrawal period was tested several times during 14 days with hexobarbital
A 59-year-old woman who is awake yet unresponsive and stuporous after liver transplantation.
Insung Chung et al.
Chest, 143(4), 1163-1165 (2013-04-03)
Nicole H McClellan et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 69(21), 1881-1884 (2012-11-01)
The case of a patient with metastatic colorectal cancer who had a seizure during his intial cetuximab infusion is reported. A 54-year-old Asian man received his first infusion of cetuximab after pretreatment with ondansetron, ranitidine, diphenhydramine, and dexamethasone. Approximately 15
View All Related Papers